Squarepoint’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-448,558
| Closed | -$839K | – | 4779 |
|
|
2025
Q4 | $839K | Sell |
448,558
-483,518
| -52% | -$929K | ﹤0.01% | 2756 |
|
|
2025
Q3 | $1.19M | Buy |
932,076
+637,492
| +216% | +$863K | ﹤0.01% | 2538 |
|
|
2025
Q2 | $365K | Buy |
294,584
+215,006
| +270% | +$248K | ﹤0.01% | 3538 |
|
|
2025
Q1 | $93.9K | Buy |
79,578
+69,400
| +682% | +$106K | ﹤0.01% | 4234 |
|
|
2024
Q4 | $18.6K | Sell |
10,178
-32,862
| -76% | -$64.1K | ﹤0.01% | 4939 |
|
|
2024
Q3 | $73.2K | Sell |
43,040
-481,568
| -92% | -$791K | ﹤0.01% | 3935 |
|
|
2024
Q2 | $719K | Buy |
+524,608
| New | +$1.06M | ﹤0.01% | 2800 |
|
|
2023
Q4 | – | Sell |
-247,861
| Closed | -$2.07M | – | 4362 |
|
|
2023
Q3 | $2.07M | Buy |
247,861
+148,917
| +151% | +$1.7M | 0.01% | 1797 |
|
|
2023
Q2 | $1.32M | Buy |
+98,944
| New | +$1.2M | ﹤0.01% | 1959 |
|
|
2023
Q1 | – | Sell |
-310,800
| Closed | -$2.54M | – | 3645 |
|
|
2022
Q4 | $2.54M | Sell |
310,800
-341,602
| -52% | -$2.94M | 0.01% | 1227 |
|
|
2022
Q3 | $3.79M | Sell |
652,402
-204,145
| -24% | -$1.17M | 0.02% | 923 |
|
|
2022
Q2 | $3.79M | Buy |
856,547
+37,077
| +5% | +$225K | 0.02% | 820 |
|
|
2022
Q1 | $7.46M | Buy |
819,470
+800,175
| +4,147% | +$9.21M | 0.03% | 543 |
|
|
2021
Q4 | $395K | Sell |
19,295
-357,381
| -95% | -$8.62M | ﹤0.01% | 2305 |
|
|
2021
Q3 | $9.62M | Buy |
376,676
+336,247
| +832% | +$9.96M | 0.03% | 513 |
|
|
2021
Q2 | $1.41M | Buy |
40,429
+6,907
| +21% | +$201K | 0.01% | 1390 |
|
|
2021
Q1 | $1.12M | Sell |
33,522
-24,398
| -42% | -$854K | 0.01% | 1418 |
|
|
2020
Q4 | $1.5M | Buy |
+57,920
| New | +$984K | 0.01% | 1083 |
|
|
2020
Q3 | – | Sell |
-75,635
| Closed | -$261K | – | 2748 |
|
|
2020
Q2 | $261K | Buy |
+75,635
| New | +$257K | ﹤0.01% | 1690 |
|
|
2020
Q1 | – | Sell |
-191,776
| Closed | -$986K | – | 2343 |
|
|
2019
Q4 | $986K | Buy |
191,776
+159,300
| +491% | +$810K | 0.01% | 1340 |
|
|
2019
Q3 | $168K | Sell |
32,476
-187,191
| -85% | -$1.05M | ﹤0.01% | 2119 |
|
|
2019
Q2 | $1.33M | Sell |
219,667
-20,693
| -9% | -$145K | 0.01% | 1093 |
|
|
2019
Q1 | $1.74M | Sell |
240,360
-25,174
| -9% | -$182K | 0.02% | 836 |
|
|
2018
Q4 | $1.97M | Buy |
+265,534
| New | +$1.68M | 0.02% | 681 |
|
|
2018
Q1 | – | Sell |
-14,977
| Closed | -$40K | – | 2019 |
|
|
2017
Q4 | $40K | Buy |
+14,977
| New | +$52.4K | ﹤0.01% | 2026 |
|
|
2016
Q4 | – | Sell |
-13,097
| Closed | -$117K | – | 1885 |
|
|
2016
Q3 | $117K | Buy |
+13,097
| New | +$109K | 0.01% | 945 |
|
|
2016
Q1 | – | Sell |
-15,100
| Closed | -$198K | – | 1376 |
|
|
2015
Q4 | $198K | Buy |
+15,100
| New | +$135K | 0.02% | 1002 |
|
|
2015
Q1 | – | Sell |
-22,400
| Closed | -$176K | – | 481 |
|
|
2014
Q4 | $176K | Buy |
+22,400
| New | +$143K | 0.17% | 178 |
|
Other funds holding PACB
AIM
VCM
NAMA
Squarepoint's PACB Position: Q1 2026 in Review
Squarepoint sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 448,558 shares — an estimated $839K sold.
Squarepoint first reported a position in PACB in Q4 2014 and held it in 28 quarters. The position peaked at $9.62M in Q3 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Squarepoint reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 448,558 Pacific Biosciences shares in Q1 2026, an estimated $839K.
- Squarepoint first reported a position in Pacific Biosciences in Q4 2014 and held it in 28 quarters.
- Squarepoint's Pacific Biosciences position peaked at $9.62M in Q3 2021.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.